Clinical trials: Bladder
Papillary-Only Non-muscle-invasive Bladder Cancer
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with…
- Trial name
- NiBladder 2 (NCT07726992)
- Testing
- SHR-1501+BCG
- Where
- 2 sites in China
- Volunteers
- 750 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Overactive Bladder(OAB)
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
A randomized, open-label, single-dose, replicate crossover study to compare the pharmacokinetics and safety in healthy adult volunteers following oral administration of JLP-2002
- Trial name
- NCT04914221
- Testing
- JLP-2002, Comparator
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Melanoma, NSCLC
A Study of BCD-135 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, NSCLC, Renal Cell Carcinoma, Bladder Cancer
- Trial name
- NCT03464032
- Testing
- BCD-135
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Biocad
Urinary Bladder Cancer
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis…
- Trial name
- NCT02720367
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Taris Biomedical LLC
Non-muscle Invasive Bladder Cancer
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of…
- Trial name
- ADVANCED-1 (NCT05085977)
- Testing
- TARA-002
- Where
- 14 sites in United States, Moldova and 2 more
- Volunteers
- 12 people
- Sponsor
- Protara Therapeutics
Stress Urinary Incontinence (SUI)
A Study of Two Versions of the Uresta Pessary Handle for Women With Stress Urinary Incontinence
The goal of this clinical trial is to learn if a new handle design for the uresta pessary works better than the current handle design for women when they are using the pessary.
- Trial name
- NCT07706491
- Testing
- pessary handle
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Resilia Inc.
BPH, BOO - Bladder Outflow Obstruction
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
This study evaluates the long term safety and efficacy of use of the Butterfly Medical's prostatic retraction device in Benign Prostatic Hyperplasia (BPH) Patients.
- Conditions
- BPH, BOO - Bladder Outflow Obstruction, Enlarged Prostate (BPH)
- Trial name
- NCT05330520
- Testing
- Butterfly Medical Prostatic Retraction Device ("the Butterfly device") removal/replacement
- Where
- 2 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Butterfly Medical Ltd.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Overactive Bladder (OAB)
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.
- Trial name
- NCT03572231
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 15 sites in South Korea, Taiwan
- Volunteers
- 805 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Overactive Bladder Syndrome
Study of V117957 in Overactive Bladder Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
- Trial name
- NCT06024642
- Testing
- V117957
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- Imbrium Therapeutics
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Urinary Bladder, Overactive
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
- Trial name
- NCT00645281
- Testing
- tolterodine extended release
- Where
- 96 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Bladder Cancer
Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer
The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.
- Trial name
- NCT00634621
- Testing
- Hexaminolevulinate (Hexvix)
- Where
- Spain
- Volunteers
- 283 people
- Sponsor
- GE Healthcare
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Overactive Bladder
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.
- Trial name
- NCT03643380
- Testing
- AHLeveeS System
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Neuspera Medical, Inc.
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.